title: Secondary malignancy after imatinib therapy: eight cases and review of the literature.
abstract: Chronic myeloid leukemia (CML) is a clonal stem cell disorder, and imatinib is a small molecule inhibitor of Bcr-Abl tyrosine kinase (TK) used in cases with CML. Immediate and short-term side effects of this tyrosine kinase inhibitor (TKI) are well known, but the long-term side effects have not yet been clearly identified. Although an increased risk of secondary cancer in cases treated by imatinib was not found in two large series, secondary malignancies have been reported in some cases using TKIs, and this issue is important in daily clinical practice for clinicians. Here we report eight cases with neoplasias that developed during imatinib therapy and review secondary malignant disorders occurring during/after imatinib treatment.
authors.affiliation: Department of Medical Oncology, Faculty of Medicine, Çukurova University, Adana, Turkey. berboz@hotmail.com
authors.forename: Berna Bozkurt
authors.initials: BB
authors.lastname: Duman
authors.forename: Semra
authors.initials: S
authors.lastname: Paydas
authors.forename: Umut
authors.initials: U
authors.lastname: Disel
authors.forename: Ayberk
authors.initials: A
authors.lastname: Besen
authors.forename: Emel
authors.initials: E
authors.lastname: Gurkan
mesh_terms: D000328:Adult; D000368:Aged; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000139:chemically induced*; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate